LP0162-1335: A single (assessor) blinded, randomized, parallel-group, monotherapy trial to evaluate the pharmacokinetics and safety of tralokinumab in children (age 6 to <12 years) with moderate to-severe atopic dermatitis. - TRAPEDS 1 (TRAlokinumab PEDiatric trial no. 1).

Treatment of moderate-to-severe Atopic dermatitis

1. Ctrough at Week 16., 2. Cmax between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W).The endpoint will also be summarized by dosing interval within the low dose level, 3. AUC between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W).The endpoint will also be summarized by dosing interval within the low dose level, 4. Tmax between Week 12-Week14 for Q2W (Week 12-Week 16 for Q4W).The endpoint will also be summarized by dosing interval within the low dose level

1. Number of treatment‑emergent adverse events in the initial treatment period (Week 0 to Week 16)., 2. Anti-drug antibodies (status) in the initial treatment period (Week 0 to Week 16)., 3. Number of treatment‑emergent adverse events in the open-label treatment period (Week 16 to Week 68)., 4. Anti-drug antibodies (status) in the open-label treatment period (Week 16 to Week 68)., 5. Number of treatment-emergent adverse events in the long term extension treatment period (Week 68 to end of treatment visit (The end-of-treatment visit is held 2 weeks after end of treatment (defined as the date of the last IMP dose for each subject))., 6. Anti-drug antibodies (status) in the long term extension treatment period (Week 68 to end-of-treatment visit (The end-of-treatment visit is held 2 weeks after end of treatment (defined as the date of the last IMP dose for each subject))., 7. Change in SCORAD from Week 0 to Week 68., 8. Change in POEM from Week 0 to Week 68., 9. Change in EASI from Week 0 to Week 68.

No related papers found yet.

Czechia, France, Netherlands, Spain